The biosimilar month in review highlights the July 1 launch of 7 adalimumab (Humira) biosimilars in the US and the cost-saving potential of increased biosimilar availability.
/PRNewswire/ With the potential to generate higher profits, big pharma companies are investing more in the adalimumab, infliximab and etanercept biosimilars.